EXHIBIT 10.26 BAYCORP HOLDINGS, LTD. RETENTION AND INCENTIVE AGREEMENT --------------------------------- This Agreement is made by and between BayCorp Holdings, Ltd., a Delaware corporation with an address 15 Rye Street, Suite 100, Portsmouth, NE...Retention and Incentive Agreement • March 31st, 2003 • Baycorp Holdings LTD • Electric services • New Hampshire
RETENTION AND INCENTIVE AGREEMENTRetention and Incentive Agreement • May 15th, 2009 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
This Retenion and Incentive Agreement (this “Agreement”) is made as of January 28, 2009 (the “Effective Date”) by and between Adventrx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark E. Erwin, an individual resident of the State of California (“Employee”). Certain capitalized terms used in this Agreement are defined in Section 12 below.
RETENTION AND INCENTIVE AGREEMENTRetention and Incentive Agreement • May 12th, 2010 • Varian Inc • Laboratory analytical instruments • California
This Retention and Incentive Agreement (this “Agreement”), dated as of January 27, 2010, is by and between Varian, Inc., a Delaware corporation (the “Company”), and Gordon B. Tredger (“Employee”).
RETENTION AND INCENTIVE AGREEMENTRetention and Incentive Agreement • February 2nd, 2009 • Adventrx Pharmaceuticals Inc • Pharmaceutical preparations • California
This Retention and Incentive Agreement (this “Agreement”) is made as of January 28, 2009 (the “Effective Date”) by and between Adventrx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Brian M. Culley, an individual resident of the State of California (“Employee”). Certain capitalized terms used in this Agreement are defined in Section 12 below.
Retention and incentive AGREEMENTRetention and Incentive Agreement • March 17th, 2017 • Caladrius Biosciences, Inc. • Services-misc health & allied services, nec • New York
This RETENTION AND INCENTIVE AGREEMENT (this “Agreement”), dated and effective as of March 16, 2017 (the “Effective Date”) is by and between Caladrius Biosciences, Inc. (the “Company” or “Caladrius”) and Robert Preti (the “Executive”).
